Abstract |
To examine the efficacy of cholinergic enhancement in senile dementia of the Alzheimer type (SDAT), oral physostigmine was given to eight patients in a cross-over trial of three dose levels and a matching placebo. A dose-related improvement in memory as measured by objective verbal memory tests was observed. Performance was significantly better on the highest dose, 2 mg every 2 h, than on the lower doses. The effect was most systematically present for very short-term memory, which raises the question of whether the improvement may involve attention rather than longer term storage and retrieval.
|
Authors | S A Beller, J E Overall, A C Swann |
Journal | Psychopharmacology
(Psychopharmacology (Berl))
Vol. 87
Issue 2
Pg. 147-51
( 1985)
ISSN: 0033-3158 [Print] Germany |
PMID | 3931138
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Administration, Oral
- Aged
- Alzheimer Disease
(drug therapy)
- Clinical Trials as Topic
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Humans
- Male
- Memory
(drug effects)
- Memory, Short-Term
(drug effects)
- Middle Aged
- Physostigmine
(administration & dosage, adverse effects, therapeutic use)
- Random Allocation
|